nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—IL1B—systemic scleroderma	0.284	0.586	CbGaD
Minocycline—MMP9—Captopril—systemic scleroderma	0.279	0.798	CbGbCtD
Minocycline—MMP9—systemic scleroderma	0.2	0.414	CbGaD
Minocycline—SLC22A6—Captopril—systemic scleroderma	0.0214	0.0613	CbGbCtD
Minocycline—SLC22A11—Methotrexate—systemic scleroderma	0.0167	0.0478	CbGbCtD
Minocycline—SLC22A7—Methotrexate—systemic scleroderma	0.0159	0.0455	CbGbCtD
Minocycline—CASP3—alveolus of lung—systemic scleroderma	0.0113	0.151	CbGeAlD
Minocycline—SLC22A8—Methotrexate—systemic scleroderma	0.00972	0.0278	CbGbCtD
Minocycline—SLC22A6—Methotrexate—systemic scleroderma	0.00677	0.0193	CbGbCtD
Minocycline—IL1B—dermis—systemic scleroderma	0.00553	0.0743	CbGeAlD
Minocycline—IL1B—skeletal joint—systemic scleroderma	0.00477	0.0641	CbGeAlD
Minocycline—MMP9—dermis—systemic scleroderma	0.00461	0.0619	CbGeAlD
Minocycline—MMP9—skeletal joint—systemic scleroderma	0.00398	0.0535	CbGeAlD
Minocycline—CASP3—artery—systemic scleroderma	0.0025	0.0336	CbGeAlD
Minocycline—CYCS—blood vessel—systemic scleroderma	0.00227	0.0306	CbGeAlD
Minocycline—CASP3—endothelium—systemic scleroderma	0.00211	0.0284	CbGeAlD
Minocycline—IL1B—artery—systemic scleroderma	0.002	0.0269	CbGeAlD
Minocycline—CASP3—blood vessel—systemic scleroderma	0.00195	0.0262	CbGeAlD
Minocycline—Doxycycline—MMP1—systemic scleroderma	0.0017	1	CrCbGaD
Minocycline—IL1B—endothelium—systemic scleroderma	0.00169	0.0227	CbGeAlD
Minocycline—MMP9—artery—systemic scleroderma	0.00167	0.0224	CbGeAlD
Minocycline—IL1B—blood vessel—systemic scleroderma	0.00156	0.0209	CbGeAlD
Minocycline—MMP9—endothelium—systemic scleroderma	0.00141	0.0189	CbGeAlD
Minocycline—MMP9—blood vessel—systemic scleroderma	0.0013	0.0174	CbGeAlD
Minocycline—CASP1—connective tissue—systemic scleroderma	0.00121	0.0163	CbGeAlD
Minocycline—CYCS—connective tissue—systemic scleroderma	0.00117	0.0157	CbGeAlD
Minocycline—CASP1—skin of body—systemic scleroderma	0.00109	0.0147	CbGeAlD
Minocycline—CYCS—smooth muscle tissue—systemic scleroderma	0.00107	0.0143	CbGeAlD
Minocycline—CYCS—skin of body—systemic scleroderma	0.00105	0.0142	CbGeAlD
Minocycline—CASP3—connective tissue—systemic scleroderma	0.000999	0.0134	CbGeAlD
Minocycline—CYCS—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.000981	0.308	CbGdCrCtD
Minocycline—CASP3—smooth muscle tissue—systemic scleroderma	0.000914	0.0123	CbGeAlD
Minocycline—CASP3—skin of body—systemic scleroderma	0.000902	0.0121	CbGeAlD
Minocycline—CASP1—digestive system—systemic scleroderma	0.000875	0.0118	CbGeAlD
Minocycline—CYCS—digestive system—systemic scleroderma	0.000842	0.0113	CbGeAlD
Minocycline—CASP1—tendon—systemic scleroderma	0.000833	0.0112	CbGeAlD
Minocycline—IL1B—connective tissue—systemic scleroderma	0.000798	0.0107	CbGeAlD
Minocycline—CASP1—lung—systemic scleroderma	0.000731	0.00982	CbGeAlD
Minocycline—IL1B—smooth muscle tissue—systemic scleroderma	0.00073	0.00981	CbGeAlD
Minocycline—CASP3—digestive system—systemic scleroderma	0.000722	0.0097	CbGeAlD
Minocycline—IL1B—skin of body—systemic scleroderma	0.000721	0.00968	CbGeAlD
Minocycline—VEGFA—smooth muscle tissue—systemic scleroderma	0.000718	0.00965	CbGeAlD
Minocycline—CYCS—lung—systemic scleroderma	0.000704	0.00945	CbGeAlD
Minocycline—CASP3—tendon—systemic scleroderma	0.000687	0.00923	CbGeAlD
Minocycline—MMP9—connective tissue—systemic scleroderma	0.000665	0.00894	CbGeAlD
Minocycline—MMP9—smooth muscle tissue—systemic scleroderma	0.000608	0.00818	CbGeAlD
Minocycline—CASP3—lung—systemic scleroderma	0.000603	0.0081	CbGeAlD
Minocycline—MMP9—skin of body—systemic scleroderma	0.000601	0.00807	CbGeAlD
Minocycline—IL1B—digestive system—systemic scleroderma	0.000576	0.00775	CbGeAlD
Minocycline—VEGFA—Enalapril—Captopril—systemic scleroderma	0.000561	0.176	CbGdCrCtD
Minocycline—IL1B—tendon—systemic scleroderma	0.000549	0.00737	CbGeAlD
Minocycline—VEGFA—tendon—systemic scleroderma	0.00054	0.00725	CbGeAlD
Minocycline—ALOX5—connective tissue—systemic scleroderma	0.000526	0.00707	CbGeAlD
Minocycline—IL1B—lung—systemic scleroderma	0.000481	0.00647	CbGeAlD
Minocycline—ALOX5—smooth muscle tissue—systemic scleroderma	0.000481	0.00646	CbGeAlD
Minocycline—MMP9—digestive system—systemic scleroderma	0.00048	0.00645	CbGeAlD
Minocycline—VEGFA—lung—systemic scleroderma	0.000473	0.00636	CbGeAlD
Minocycline—MMP9—tendon—systemic scleroderma	0.000457	0.00614	CbGeAlD
Minocycline—SLC22A11—digestive system—systemic scleroderma	0.000455	0.00612	CbGeAlD
Minocycline—SLC22A7—digestive system—systemic scleroderma	0.000444	0.00597	CbGeAlD
Minocycline—MMP9—lung—systemic scleroderma	0.000401	0.00539	CbGeAlD
Minocycline—ALOX5—digestive system—systemic scleroderma	0.00038	0.0051	CbGeAlD
Minocycline—IL1B—Methylprednisolone—Mometasone—systemic scleroderma	0.000336	0.105	CbGdCrCtD
Minocycline—ALOX5—lung—systemic scleroderma	0.000317	0.00426	CbGeAlD
Minocycline—MMP9—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000264	0.00304	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.00026	0.00299	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—FBN1—systemic scleroderma	0.000259	0.00298	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL1A—systemic scleroderma	0.000256	0.00294	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—CD40LG—systemic scleroderma	0.000254	0.00293	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—RHOB—systemic scleroderma	0.000254	0.00292	CbGpPWpGaD
Minocycline—CASP3—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000253	0.00291	CbGpPWpGaD
Minocycline—MMP9—Matrix Metalloproteinases—MMP2—systemic scleroderma	0.000252	0.0029	CbGpPWpGaD
Minocycline—MMP9—Osteopontin-mediated events—MMP2—systemic scleroderma	0.000246	0.00283	CbGpPWpGaD
Minocycline—VEGFA—Angiogenesis—NOS3—systemic scleroderma	0.000245	0.00282	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL13—systemic scleroderma	0.000245	0.00282	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000244	0.00281	CbGpPWpGaD
Minocycline—MMP9—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	0.00024	0.00277	CbGpPWpGaD
Minocycline—CYCS—AGE/RAGE pathway—MMP2—systemic scleroderma	0.00024	0.00276	CbGpPWpGaD
Minocycline—MMP9—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.000239	0.00276	CbGpPWpGaD
Minocycline—MMP9—amb2 Integrin signaling—MMP2—systemic scleroderma	0.000239	0.00276	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000238	0.00274	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000236	0.00272	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000234	0.00269	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000233	0.00268	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—IL1A—systemic scleroderma	0.000232	0.00267	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—CD40LG—systemic scleroderma	0.00023	0.00265	CbGpPWpGaD
Minocycline—IL1B—IL27-mediated signaling events—TGFB1—systemic scleroderma	0.000228	0.00263	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000227	0.00261	CbGpPWpGaD
Minocycline—IL1B—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000226	0.0026	CbGpPWpGaD
Minocycline—CYCS—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000224	0.00258	CbGpPWpGaD
Minocycline—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000224	0.00258	CbGpPWpGaD
Minocycline—IL1B—Cytokines and Inflammatory Response—TGFB1—systemic scleroderma	0.000222	0.00255	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000217	0.0025	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000214	0.00246	CbGpPWpGaD
Minocycline—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000213	0.00245	CbGpPWpGaD
Minocycline—IL1B—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000213	0.00245	CbGpPWpGaD
Minocycline—VEGFA—VEGFR1 specific signals—NOS3—systemic scleroderma	0.000211	0.00242	CbGpPWpGaD
Minocycline—MMP9—Collagen degradation—MMP2—systemic scleroderma	0.000209	0.0024	CbGpPWpGaD
Minocycline—IL1B—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000209	0.0024	CbGpPWpGaD
Minocycline—CASP3—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000209	0.0024	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Mometasone—systemic scleroderma	0.000208	0.0654	CbGdCrCtD
Minocycline—CASP3—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000206	0.00237	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000203	0.00233	CbGpPWpGaD
Minocycline—MMP9—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000202	0.00233	CbGpPWpGaD
Minocycline—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.0002	0.0023	CbGpPWpGaD
Minocycline—CASP3—LPA receptor mediated events—MMP2—systemic scleroderma	0.000198	0.00228	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—CTLA4—systemic scleroderma	0.000197	0.00227	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000197	0.00227	CbGpPWpGaD
Minocycline—VEGFA—Angiogenesis—MMP9—systemic scleroderma	0.000197	0.00226	CbGpPWpGaD
Minocycline—CASP3—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.000197	0.00226	CbGpPWpGaD
Minocycline—MMP9—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000196	0.00226	CbGpPWpGaD
Minocycline—CASP3—Syndecan-2-mediated signaling events—TGFB1—systemic scleroderma	0.000194	0.00224	CbGpPWpGaD
Minocycline—CASP3—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000193	0.00222	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL1A—systemic scleroderma	0.000186	0.00214	CbGpPWpGaD
Minocycline—VEGFA—Enalapril—Lisinopril—systemic scleroderma	0.000185	0.0581	CbGdCrCtD
Minocycline—IL1B—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000184	0.00212	CbGpPWpGaD
Minocycline—MMP9—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000184	0.00212	CbGpPWpGaD
Minocycline—IL1B—Folate Metabolism—CCL2—systemic scleroderma	0.000184	0.00212	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Prednisone—systemic scleroderma	0.000183	0.0575	CbGdCrCtD
Minocycline—CASP3—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000181	0.00208	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000181	0.00208	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000181	0.00208	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL1A—systemic scleroderma	0.00018	0.00208	CbGpPWpGaD
Minocycline—CYCS—AGE/RAGE pathway—MMP9—systemic scleroderma	0.00018	0.00207	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—FBN1—systemic scleroderma	0.00018	0.00207	CbGpPWpGaD
Minocycline—VEGFA—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000179	0.00206	CbGpPWpGaD
Minocycline—MMP9—EPH-ephrin mediated repulsion of cells—MMP2—systemic scleroderma	0.000173	0.00199	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—IL1A—systemic scleroderma	0.000168	0.00193	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000165	0.0019	CbGpPWpGaD
Minocycline—CYCS—Alzheimers Disease—IL1B—systemic scleroderma	0.000165	0.0019	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000164	0.00189	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000162	0.00187	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000156	0.00179	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL1A—systemic scleroderma	0.000154	0.00177	CbGpPWpGaD
Minocycline—CASP1—Direct p53 effectors—MMP2—systemic scleroderma	0.000153	0.00177	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—CD40LG—systemic scleroderma	0.000153	0.00176	CbGpPWpGaD
Minocycline—VEGFA—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000152	0.00175	CbGpPWpGaD
Minocycline—CASP3—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.000152	0.00175	CbGpPWpGaD
Minocycline—VEGFA—Glypican 1 network—TGFB1—systemic scleroderma	0.000152	0.00175	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—RHOB—systemic scleroderma	0.000151	0.00173	CbGpPWpGaD
Minocycline—CASP1—Signaling by Interleukins—IL1B—systemic scleroderma	0.00015	0.00173	CbGpPWpGaD
Minocycline—CASP3—LPA receptor mediated events—MMP9—systemic scleroderma	0.000149	0.00171	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000149	0.00171	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000148	0.00171	CbGpPWpGaD
Minocycline—IL1B—Leptin signaling pathway—NOS3—systemic scleroderma	0.000148	0.0017	CbGpPWpGaD
Minocycline—IL1B—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000146	0.00168	CbGpPWpGaD
Minocycline—CASP3—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000145	0.00167	CbGpPWpGaD
Minocycline—IL1B—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000145	0.00166	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000143	0.00164	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000142	0.00164	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000142	0.00163	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—COL1A2—systemic scleroderma	0.000142	0.00163	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000142	0.00163	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.00014	0.00161	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Mometasone—systemic scleroderma	0.000139	0.0436	CbGdCrCtD
Minocycline—CASP3—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000139	0.0016	CbGpPWpGaD
Minocycline—MMP9—LPA receptor mediated events—MMP2—systemic scleroderma	0.000138	0.00158	CbGpPWpGaD
Minocycline—MMP9—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.000137	0.00157	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000135	0.00155	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000135	0.00155	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000134	0.00155	CbGpPWpGaD
Minocycline—MMP9—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000134	0.00154	CbGpPWpGaD
Minocycline—CASP3—Alzheimers Disease—IL1B—systemic scleroderma	0.000133	0.00154	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL1B—systemic scleroderma	0.000133	0.00154	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000133	0.00154	CbGpPWpGaD
Minocycline—MMP9—Syndecan-1-mediated signaling events—TGFB1—systemic scleroderma	0.000129	0.00149	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—ITGAM—systemic scleroderma	0.000129	0.00148	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL1A—systemic scleroderma	0.000129	0.00148	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000129	0.00148	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—CCL2—systemic scleroderma	0.000128	0.00147	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—ITGAM—systemic scleroderma	0.000127	0.00147	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CD247—systemic scleroderma	0.000127	0.00147	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000127	0.00146	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000126	0.00145	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000126	0.00145	CbGpPWpGaD
Minocycline—MMP9—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000126	0.00145	CbGpPWpGaD
Minocycline—VEGFA—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000124	0.00143	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000123	0.00142	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000121	0.0014	CbGpPWpGaD
Minocycline—VEGFA—SHP2 signaling—NOS3—systemic scleroderma	0.000121	0.00139	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL1A—systemic scleroderma	0.000121	0.00139	CbGpPWpGaD
Minocycline—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.000119	0.00137	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000119	0.00137	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—BLK—systemic scleroderma	0.000119	0.00137	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—CCL2—systemic scleroderma	0.000116	0.00133	CbGpPWpGaD
Minocycline—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000115	0.00132	CbGpPWpGaD
Minocycline—CASP3—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000114	0.00132	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000114	0.00131	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisone—systemic scleroderma	0.000113	0.0356	CbGdCrCtD
Minocycline—MMP9—Axon guidance—RHOB—systemic scleroderma	0.000113	0.0013	CbGpPWpGaD
Minocycline—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000107	0.00123	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000106	0.00122	CbGpPWpGaD
Minocycline—MMP9—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.000106	0.00122	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—TGFB1—systemic scleroderma	0.000104	0.00119	CbGpPWpGaD
Minocycline—MMP9—EPH-Ephrin signaling—MMP2—systemic scleroderma	0.000101	0.00116	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—RHOB—systemic scleroderma	9.82e-05	0.00113	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL1B—systemic scleroderma	9.68e-05	0.00111	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—TGFB1—systemic scleroderma	9.38e-05	0.00108	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—IL1B—systemic scleroderma	9.35e-05	0.00108	CbGpPWpGaD
Minocycline—VEGFA—Differentiation Pathway—TGFB1—systemic scleroderma	9.31e-05	0.00107	CbGpPWpGaD
Minocycline—CASP3—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	9.18e-05	0.00106	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—MMP9—systemic scleroderma	9.13e-05	0.00105	CbGpPWpGaD
Minocycline—VEGFA—Endochondral Ossification—MMP9—systemic scleroderma	8.97e-05	0.00103	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	8.95e-05	0.00103	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	8.86e-05	0.00102	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—CCL2—systemic scleroderma	8.86e-05	0.00102	CbGpPWpGaD
Minocycline—VEGFA—EPH-Ephrin signaling—MMP2—systemic scleroderma	8.78e-05	0.00101	CbGpPWpGaD
Minocycline—MMP9—Endochondral Ossification—TGFB1—systemic scleroderma	8.52e-05	0.00098	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Mometasone—systemic scleroderma	8.5e-05	0.0267	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Mometasone—systemic scleroderma	8.5e-05	0.0267	CbGdCrCtD
Minocycline—IL1B—TCR Signaling Pathway—TGFB1—systemic scleroderma	8.46e-05	0.000973	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	8.42e-05	0.000969	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	8.28e-05	0.000953	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—MMP9—systemic scleroderma	8.26e-05	0.000951	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—MMP1—systemic scleroderma	8.24e-05	0.000948	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	8.21e-05	0.000945	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—RHOB—systemic scleroderma	8.07e-05	0.000929	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL1B—systemic scleroderma	8.04e-05	0.000925	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—TGFB1—systemic scleroderma	7.93e-05	0.000913	CbGpPWpGaD
Minocycline—CASP1—Immune System—CSK—systemic scleroderma	7.89e-05	0.000908	CbGpPWpGaD
Minocycline—CASP1—Immune System—IRF5—systemic scleroderma	7.76e-05	0.000893	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	7.76e-05	0.000893	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	7.74e-05	0.000891	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisone—systemic scleroderma	7.58e-05	0.0238	CbGdCrCtD
Minocycline—CASP3—Spinal Cord Injury—TGFB1—systemic scleroderma	7.52e-05	0.000866	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.48e-05	0.000861	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	7.47e-05	0.00086	CbGpPWpGaD
Minocycline—CASP1—Immune System—IRF8—systemic scleroderma	7.42e-05	0.000854	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD247—systemic scleroderma	7.42e-05	0.000854	CbGpPWpGaD
Minocycline—CASP1—Immune System—ITGAM—systemic scleroderma	7.42e-05	0.000854	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	7.41e-05	0.000853	CbGpPWpGaD
Minocycline—VEGFA—Endochondral Ossification—TGFB1—systemic scleroderma	7.39e-05	0.000851	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—SELP—systemic scleroderma	7.36e-05	0.000848	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—IL1B—systemic scleroderma	7.3e-05	0.00084	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	7.02e-05	0.000808	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—RHOB—systemic scleroderma	7.01e-05	0.000807	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—NOS3—systemic scleroderma	7e-05	0.000805	CbGpPWpGaD
Minocycline—CASP1—Immune System—TNFAIP3—systemic scleroderma	6.95e-05	0.0008	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—RHOB—systemic scleroderma	6.88e-05	0.000791	CbGpPWpGaD
Minocycline—CASP1—Immune System—BLK—systemic scleroderma	6.86e-05	0.00079	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TGFB1—systemic scleroderma	6.81e-05	0.000784	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL1B—systemic scleroderma	6.72e-05	0.000773	CbGpPWpGaD
Minocycline—VEGFA—EPH-Ephrin signaling—MMP9—systemic scleroderma	6.6e-05	0.000759	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—MMP2—systemic scleroderma	6.38e-05	0.000734	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—CSK—systemic scleroderma	6.26e-05	0.000721	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—TGFB1—systemic scleroderma	6.25e-05	0.000719	CbGpPWpGaD
Minocycline—VEGFA—Platelet degranulation—TGFB1—systemic scleroderma	6.19e-05	0.000712	CbGpPWpGaD
Minocycline—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	5.89e-05	0.000678	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—ITGAM—systemic scleroderma	5.89e-05	0.000678	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL1A—systemic scleroderma	5.87e-05	0.000676	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—MMP1—systemic scleroderma	5.72e-05	0.000658	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TGFB1—systemic scleroderma	5.67e-05	0.000653	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.67e-05	0.000652	CbGpPWpGaD
Minocycline—CASP1—Immune System—CTLA4—systemic scleroderma	5.62e-05	0.000647	CbGpPWpGaD
Minocycline—CYCS—Metabolism—HSPG2—systemic scleroderma	5.41e-05	0.000622	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TGFB1—systemic scleroderma	5.22e-05	0.000601	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TGFB1—systemic scleroderma	5.13e-05	0.000591	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.12e-05	0.000589	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SMAD7—systemic scleroderma	5e-05	0.000575	CbGpPWpGaD
Minocycline—IL1B—Immune System—CSK—systemic scleroderma	4.93e-05	0.000568	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRF5—systemic scleroderma	4.85e-05	0.000558	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—MMP9—systemic scleroderma	4.79e-05	0.000552	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	4.67e-05	0.000537	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRF8—systemic scleroderma	4.64e-05	0.000534	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD247—systemic scleroderma	4.64e-05	0.000534	CbGpPWpGaD
Minocycline—IL1B—Immune System—ITGAM—systemic scleroderma	4.64e-05	0.000534	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Prednisone—systemic scleroderma	4.63e-05	0.0146	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Prednisone—systemic scleroderma	4.63e-05	0.0146	CbGdCrCtD
Minocycline—CASP1—Immune System—HLA-DQB1—systemic scleroderma	4.63e-05	0.000533	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Mometasone—systemic scleroderma	4.54e-05	0.0143	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Mometasone—systemic scleroderma	4.54e-05	0.0143	CbGdCrCtD
Minocycline—MMP9—Extracellular matrix organization—MMP2—systemic scleroderma	4.43e-05	0.000509	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1A—systemic scleroderma	4.4e-05	0.000506	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD40LG—systemic scleroderma	4.37e-05	0.000503	CbGpPWpGaD
Minocycline—IL1B—Immune System—TNFAIP3—systemic scleroderma	4.34e-05	0.0005	CbGpPWpGaD
Minocycline—IL1B—Immune System—BLK—systemic scleroderma	4.29e-05	0.000494	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CTGF—systemic scleroderma	4.1e-05	0.000472	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—TGFB1—systemic scleroderma	3.95e-05	0.000455	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RHOB—systemic scleroderma	3.87e-05	0.000445	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—MMP2—systemic scleroderma	3.76e-05	0.000432	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HSPG2—systemic scleroderma	3.65e-05	0.00042	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CSK—systemic scleroderma	3.52e-05	0.000405	CbGpPWpGaD
Minocycline—IL1B—Immune System—CTLA4—systemic scleroderma	3.51e-05	0.000404	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SMAD7—systemic scleroderma	3.47e-05	0.000399	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—HSPG2—systemic scleroderma	3.33e-05	0.000383	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—MMP2—systemic scleroderma	3.26e-05	0.000375	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.08e-05	0.000355	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SMAD7—systemic scleroderma	3.01e-05	0.000347	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—MMP1—systemic scleroderma	2.95e-05	0.00034	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DQB1—systemic scleroderma	2.89e-05	0.000333	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL1A—systemic scleroderma	2.75e-05	0.000316	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.74e-05	0.000316	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—TGFB1—systemic scleroderma	2.74e-05	0.000316	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD40LG—systemic scleroderma	2.73e-05	0.000315	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RHOB—systemic scleroderma	2.69e-05	0.000309	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—MMP2—systemic scleroderma	2.68e-05	0.000309	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HSPG2—systemic scleroderma	2.53e-05	0.000291	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CTGF—systemic scleroderma	2.52e-05	0.000291	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Prednisone—systemic scleroderma	2.47e-05	0.00777	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisone—systemic scleroderma	2.47e-05	0.00777	CbGdCrCtD
Minocycline—VEGFA—Axon guidance—MMP9—systemic scleroderma	2.45e-05	0.000282	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CSK—systemic scleroderma	2.45e-05	0.000281	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RHOB—systemic scleroderma	2.33e-05	0.000268	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—MMP2—systemic scleroderma	2.33e-05	0.000268	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1B—systemic scleroderma	2.29e-05	0.000264	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HSPG2—systemic scleroderma	2.2e-05	0.000253	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS3—systemic scleroderma	2.14e-05	0.000246	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CSK—systemic scleroderma	2.12e-05	0.000244	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EDN1—systemic scleroderma	1.97e-05	0.000227	CbGpPWpGaD
Minocycline—CYCS—Metabolism—NOS3—systemic scleroderma	1.78e-05	0.000205	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—MMP9—systemic scleroderma	1.75e-05	0.000201	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TGFB1—systemic scleroderma	1.66e-05	0.000191	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TGFB1—systemic scleroderma	1.44e-05	0.000166	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TGFB1—systemic scleroderma	1.41e-05	0.000163	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EDN1—systemic scleroderma	1.37e-05	0.000158	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL2—systemic scleroderma	1.35e-05	0.000155	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NOS3—systemic scleroderma	1.2e-05	0.000138	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000137	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NOS3—systemic scleroderma	1.1e-05	0.000126	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MMP9—systemic scleroderma	9.65e-06	0.000111	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL2—systemic scleroderma	9.37e-06	0.000108	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NOS3—systemic scleroderma	8.35e-06	9.61e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL2—systemic scleroderma	8.14e-06	9.36e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TGFB1—systemic scleroderma	7.96e-06	9.16e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NOS3—systemic scleroderma	7.25e-06	8.35e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MMP9—systemic scleroderma	5.82e-06	6.7e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TGFB1—systemic scleroderma	5.52e-06	6.36e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TGFB1—systemic scleroderma	4.79e-06	5.52e-05	CbGpPWpGaD
